Two vaccines under development against the emerging coronavirus (Covid-19), one British and one Chinese, have shown a positive effect on the immune response of the volunteers, according to the results of two separate clinical trials that have also shown that they are safe for patients, and their results were published yesterday, the British medical journal The Lancet.
The first vaccine, developed by Oxford University in partnership with AstraZeneca, produced a “strong immune response” in an experiment on more than 1,000 patients, while the second vaccine, developed with the support of the Chinese company “Cansino Biologics”, has achieved a good result in the field of antibody production in the majority among 500 patients in a separate trial.
The University of Oxford said that the interim experiments that were conducted on different samples with an anti-covid-19 drug showed that the drug had a positive effect on the immunity of volunteers. The university added that the vaccine doses were given to 1077 volunteers in the period between last April as part of the first phase of the experiments until mid-July. And doses proved that the vaccine had satisfactory results in strengthening the immune system and body cells in general, after 56 days of obtaining the vaccine.
The researchers said in the journal “Lancet” that the vaccine for the emerging corona virus, which is being developed by Oxford University, in cooperation with the company “AstraZeneca” appears to be safe and provides immunity from the disease. They added that the immune reactions may be stronger after receiving a second dose of the vaccine.
British Prime Minister Boris Johnson described the initial results of clinical trials on the “Oxford and AstraZeneca” vaccine as very positive news, calling for more experiments.
On the other hand, Russia expressed its hope to produce with its partners about 200 million doses of a vaccine against the emerging corona virus this year in the event of successful clinical tests. The first clinical trials in Russia ended with the second stage ending up to the third of August, explaining that the third stage of the trials will take place on Russian soil and in several other countries.
Meanwhile, the chief scientist of the World Health Organization, Sumaya Swaminathan, told Deutsche Presse-Agentur dpa that vaccination against the Corona virus could begin widespread in the middle of next year, expressing cautious optimism about the state of the research and development process .
“We now have more than 20 candidate vaccines for clinical studies,” she added. So we hope that two of them will succeed, and it would be very unfortunate for all of them to fail. If we were very pragmatic, we are looking forward to the middle of 2021 when we will have a vaccine that can be widely spread, and of course it is impossible to predict. ”
Swaminathan added that the global race to develop a vaccine was the fastest schedule we have ever seen, noting that there had only been three months between the time of the genome sequencing of the virus in January and the start of the first trial.
A statistic revealed to Reuters news agency that more than 14.38 million people were infected with the new corona virus worldwide, and that 604 thousand and 232 people died from the virus. HIV infections have been recorded in more than 210 countries and regions.
Oxford: Experiments confirmed that the university vaccine strengthens the immune system.
The World Health Organization: 20 vaccines against Corona in clinical studies.
A million cases of «Covid-19» around the world.
Follow our latest local and sports news and the latest political and economic developments via Google news